Earnings ·
Caribou Biosciences reported second quarter 2026 financial results and provided a business update on August 13, 2026
CRBUCaribou Biosciences, Inc.
Caribou Biosciences reported second quarter 2026 financial results and provided a business update on August 13, 2026. The company posted a GAAP net loss of $24.3 million, or $0.24 per share, compared to a $54.1 million loss in the prior year period. Revenue from licensing agreements decreased to $1.5 million from $2.7 million, while R&D and G&A expenses fell to $18.9 million and $7.9 million respectively due to workforce reductions and strategic prioritization announced in April 2025. Cash and marketable securities stood at $113.8 million as of June 30, 2026, sufficient to fund operations through the end of 2027. Clinically, data presented at EHA 2026 reinforced vispa-cel's safety and efficacy in second-line large B cell lymphoma and demonstrated deep responses for CB-011 in multiple myeloma.